Compare BigBearai Holdings Inc (BBAI) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Cytokinetics Inc — how do they compare? BigBearai Holdings Inc trades at $3.29 (market cap $1.60B), while Cytokinetics Inc trades at $76.97 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 6.6× BigBearai Holdings Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | CYTK | |
|---|---|---|
Market Cap | $1.60B | $10.63B |
Sector | Technology | Technology |
52-Week High | $8.91 | $87.26 |
52-Week Low | $2.61 | $34.31 |
Enterprise Value | $1.30B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.32, up 2.79% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations. Despite negative profitability metrics (-65.2% net margin), the stock shows institutional interest with 75% analyst hold ratings. Recent news highlights defense contract wins and generative AI platform expansion for Department of War missions.
Outlook remains cautious due to persistent losses and revenue headwinds, though backlog growth and government contracts provide stability. Investment opportunity exists in AI defense specialization, but risks include execution challenges and competitive pressure. The stock requires careful monitoring of profitability improvements and contract execution.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
